» Articles » PMID: 11207318

Gene Expression of Osteoclast Differentiation Factor is Induced by Lipopolysaccharide in Mouse Osteoblasts Via Toll-like Receptors

Overview
Journal J Immunol
Date 2001 Feb 24
PMID 11207318
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoclast differentiation factor (ODF), a recently identified cytokine of the TNF family, is expressed as a membrane-associated protein in osteoblasts and stromal cells. ODF stimulates the differentiation of osteoclast precursors into osteoclasts in the presence of M-CSF. Here we investigated the effects of LPS on the gene expression of ODF in mouse osteoblasts and an osteoblast cell line and found that LPS increased the ODF mRNA level. A specific inhibitor of extracellular signal-regulated kinase or protein kinase C inhibited this up-regulation, indicating that extracellular signal-regulated kinase and protein kinase C activation was involved. A protein synthesis inhibitor, cycloheximide, rather enhanced the LPS-mediated increase of ODF mRNA, and both a neutralizing Ab of TNF-alpha and a specific inhibitor of PGE synthesis failed to block the ODF mRNA increase by native LPS. Thus, LPS directly induced ODF mRNA. Mouse osteoblasts and an osteoblast cell line constitutively expressed Toll-like receptor (TLR) 2 and 4, which are known as putative LPS receptors. ODF mRNA increases in response to synthetic lipid A were defective in primary osteoblasts from C3H/HeJ mice that contain a nonfunctional mutation in the TLR4 gene, suggesting that TLR4 plays an essential role in the process. Altogether, our results indicate that ODF gene expression is directly increased in osteoblasts by LPS treatment via TLR, and this pathway may play an important role in the pathogenesis of LPS-mediated bone disorders, such as periodontitis.

Citing Articles

Influence of metallic particles and TNF on the transcriptional regulation of NLRP3 inflammasome-associated genes in human osteoblasts.

Sellin M, Hansmann D, Bader R, Jonitz-Heincke A Front Immunol. 2024; 15:1397432.

PMID: 38751427 PMC: 11094288. DOI: 10.3389/fimmu.2024.1397432.


MyD88 in osteoclast and osteoblast lineages differentially controls bone remodeling in homeostasis and malaria.

Alshaweesh J, Dash R, Lee M, Kahyaoglu P, Erci E, Xu M Int Immunol. 2024; 36(9):451-464.

PMID: 38642134 PMC: 11319481. DOI: 10.1093/intimm/dxae023.


(D-Ala)GIP Inhibits Inflammatory Bone Resorption by Suppressing TNF-α and RANKL Expression and Directly Impeding Osteoclast Formation.

Lin A, Kitaura H, Ohori F, Noguchi T, Marahleh A, Ma J Int J Mol Sci. 2024; 25(5).

PMID: 38473802 PMC: 10931794. DOI: 10.3390/ijms25052555.


TLR4 antagonism provides short-term but not long-term clinical benefit in a full-depth cartilage defect mouse model.

Timkovich A, Holling G, Afzali M, Kisiday J, Santangelo K Connect Tissue Res. 2023; 65(1):26-40.

PMID: 37898909 PMC: 11271750. DOI: 10.1080/03008207.2023.2269257.


Glycobiology in osteoclast differentiation and function.

Yang S, He Z, Wu T, Wang S, Dai H Bone Res. 2023; 11(1):55.

PMID: 37884496 PMC: 10603120. DOI: 10.1038/s41413-023-00293-6.